Abstract
Background: Prolonged depletion of activated T cells via targeted therapy may reduce disease activity in chronic plaque psoriasis, but may potentially lead to increased risk of serious infection.Objectives: To evaluate the long-term safety profile of siplizumab, an anti-CD2 monoclonal antibody, in chronic plaque psoriasis subjects who experienced persistent siplizumab-induced lymphocyte depletion.Methods: Subjects (n=94) with absolute lymphocyte counts (ALC) >30% lower than baseline or absolute CD4 count
Original language | English (US) |
---|---|
Journal | Internet Journal of Dermatology |
Volume | 7 |
Issue number | 2 |
State | Published - 2009 |
Externally published | Yes |
Keywords
- Clinical trial
- Long-term
- Lymphocyte depletion
- Psoriasis
- Safety
ASJC Scopus subject areas
- Dermatology